Thomas Sciascia, Chief Scientific Officer at Trevi Therapeutics, Inc. (TRVI), sold 2,631 shares at $6.60 ($17K) on 2025-03-25, disclosed to the SEC on 2025-03-26.
Open-market sale of $17k TRVI by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| TRVI | SELL | 2024-05-31 | $272K | — | Filing → |